Low serum levels of tumor necrosis factor-alpha in insulin-dependent diabetic children

R. Lorini, M. De Amici, G. D'Annunzio, L. Vitali, A. Scaramuzza

Research output: Contribution to journalArticle

Abstract

We measured serum levels of tumor necrosis factor-α (TNF-α) in 48 children with insulin-dependent diabetes mellitus (IDDM), divided into two groups according to disease duration (group I <6 months and group II > 3 years): group I 15 patients, aged 2.2-13.7 years, and group II 33 patients, aged 4.5-25.5 years. Thirty-six age- and sex-matched healthy subjects served as controls. TNF-α levels were measured by immunoradiometric assay. We found that TNF-α levels were lower in all IDDM patients (29.65 ± 3.83 pg/ml) than in controls (74.74 ± 10.17 pg/ml) (p <0.0001), as well as in group I (24.07 ± 3.65 pg/ml) and group II (32.16 ± 5.29 pg/ml) as compared to controls (p <0.001). TNF-α levels were significantly lower in patients with antibodies than in those without antibodies and in controls. Similar results were found in long-standing IDDM patients. No correlation was found between serum TNF-α and chronologic age, duration of disease, metabolic control, insulin requirement and HLA typing. During a 1-year follow-up study in 12 group I patients no significant variations in TNF-α levels were observed. It has been reported that the administration of exogenous TNF suppresses the development of diabetes in nonobese diabetic mice, low producers of endogenous TNF. The results suggest that aberrant TNF-α synthesis may contribute to immune dysregulation thus favoring the development of autoimmune diseases.

Original languageEnglish
Pages (from-to)206-209
Number of pages4
JournalHormone Research
Volume43
Issue number5
Publication statusPublished - 1995

Fingerprint

Tumor Necrosis Factor-alpha
Insulin
Serum
Type 1 Diabetes Mellitus
Immunoradiometric Assay
Histocompatibility Testing
Inbred NOD Mouse
Antibodies
Metabolic Diseases
Autoimmune Diseases
Healthy Volunteers

Keywords

  • Autoimmunity
  • Tumor necrosis factor
  • Type 1 (insulin-dependent) diabetes

ASJC Scopus subject areas

  • Endocrinology

Cite this

Low serum levels of tumor necrosis factor-alpha in insulin-dependent diabetic children. / Lorini, R.; De Amici, M.; D'Annunzio, G.; Vitali, L.; Scaramuzza, A.

In: Hormone Research, Vol. 43, No. 5, 1995, p. 206-209.

Research output: Contribution to journalArticle

@article{57e3995efb2e47e8bde3cae2e0394d6a,
title = "Low serum levels of tumor necrosis factor-alpha in insulin-dependent diabetic children",
abstract = "We measured serum levels of tumor necrosis factor-α (TNF-α) in 48 children with insulin-dependent diabetes mellitus (IDDM), divided into two groups according to disease duration (group I <6 months and group II > 3 years): group I 15 patients, aged 2.2-13.7 years, and group II 33 patients, aged 4.5-25.5 years. Thirty-six age- and sex-matched healthy subjects served as controls. TNF-α levels were measured by immunoradiometric assay. We found that TNF-α levels were lower in all IDDM patients (29.65 ± 3.83 pg/ml) than in controls (74.74 ± 10.17 pg/ml) (p <0.0001), as well as in group I (24.07 ± 3.65 pg/ml) and group II (32.16 ± 5.29 pg/ml) as compared to controls (p <0.001). TNF-α levels were significantly lower in patients with antibodies than in those without antibodies and in controls. Similar results were found in long-standing IDDM patients. No correlation was found between serum TNF-α and chronologic age, duration of disease, metabolic control, insulin requirement and HLA typing. During a 1-year follow-up study in 12 group I patients no significant variations in TNF-α levels were observed. It has been reported that the administration of exogenous TNF suppresses the development of diabetes in nonobese diabetic mice, low producers of endogenous TNF. The results suggest that aberrant TNF-α synthesis may contribute to immune dysregulation thus favoring the development of autoimmune diseases.",
keywords = "Autoimmunity, Tumor necrosis factor, Type 1 (insulin-dependent) diabetes",
author = "R. Lorini and {De Amici}, M. and G. D'Annunzio and L. Vitali and A. Scaramuzza",
year = "1995",
language = "English",
volume = "43",
pages = "206--209",
journal = "Hormone Research",
issn = "0301-0163",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Low serum levels of tumor necrosis factor-alpha in insulin-dependent diabetic children

AU - Lorini, R.

AU - De Amici, M.

AU - D'Annunzio, G.

AU - Vitali, L.

AU - Scaramuzza, A.

PY - 1995

Y1 - 1995

N2 - We measured serum levels of tumor necrosis factor-α (TNF-α) in 48 children with insulin-dependent diabetes mellitus (IDDM), divided into two groups according to disease duration (group I <6 months and group II > 3 years): group I 15 patients, aged 2.2-13.7 years, and group II 33 patients, aged 4.5-25.5 years. Thirty-six age- and sex-matched healthy subjects served as controls. TNF-α levels were measured by immunoradiometric assay. We found that TNF-α levels were lower in all IDDM patients (29.65 ± 3.83 pg/ml) than in controls (74.74 ± 10.17 pg/ml) (p <0.0001), as well as in group I (24.07 ± 3.65 pg/ml) and group II (32.16 ± 5.29 pg/ml) as compared to controls (p <0.001). TNF-α levels were significantly lower in patients with antibodies than in those without antibodies and in controls. Similar results were found in long-standing IDDM patients. No correlation was found between serum TNF-α and chronologic age, duration of disease, metabolic control, insulin requirement and HLA typing. During a 1-year follow-up study in 12 group I patients no significant variations in TNF-α levels were observed. It has been reported that the administration of exogenous TNF suppresses the development of diabetes in nonobese diabetic mice, low producers of endogenous TNF. The results suggest that aberrant TNF-α synthesis may contribute to immune dysregulation thus favoring the development of autoimmune diseases.

AB - We measured serum levels of tumor necrosis factor-α (TNF-α) in 48 children with insulin-dependent diabetes mellitus (IDDM), divided into two groups according to disease duration (group I <6 months and group II > 3 years): group I 15 patients, aged 2.2-13.7 years, and group II 33 patients, aged 4.5-25.5 years. Thirty-six age- and sex-matched healthy subjects served as controls. TNF-α levels were measured by immunoradiometric assay. We found that TNF-α levels were lower in all IDDM patients (29.65 ± 3.83 pg/ml) than in controls (74.74 ± 10.17 pg/ml) (p <0.0001), as well as in group I (24.07 ± 3.65 pg/ml) and group II (32.16 ± 5.29 pg/ml) as compared to controls (p <0.001). TNF-α levels were significantly lower in patients with antibodies than in those without antibodies and in controls. Similar results were found in long-standing IDDM patients. No correlation was found between serum TNF-α and chronologic age, duration of disease, metabolic control, insulin requirement and HLA typing. During a 1-year follow-up study in 12 group I patients no significant variations in TNF-α levels were observed. It has been reported that the administration of exogenous TNF suppresses the development of diabetes in nonobese diabetic mice, low producers of endogenous TNF. The results suggest that aberrant TNF-α synthesis may contribute to immune dysregulation thus favoring the development of autoimmune diseases.

KW - Autoimmunity

KW - Tumor necrosis factor

KW - Type 1 (insulin-dependent) diabetes

UR - http://www.scopus.com/inward/record.url?scp=0028907944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028907944&partnerID=8YFLogxK

M3 - Article

C2 - 7782051

AN - SCOPUS:0028907944

VL - 43

SP - 206

EP - 209

JO - Hormone Research

JF - Hormone Research

SN - 0301-0163

IS - 5

ER -